Sunscreen in Europe Is a Cosmetic — In the US, It's a Drug: What European Exporters Must Know

A lot of European cosmetics brands hit this wall without warning. You’ve spent 18 months formulating an SPF 50 day cream, it passes every safety assessment under Regulation (EC) No 1223/2009, your CPNP notification is filed, and then your US distribution partner calls. The product can’t ship. Not because of a labeling error. Not because of a prohibited colorant. Because the UV filter driving 80% of your UVA protection isn’t on the FDA’s approved list — and there’s no quick pathway to add it.

This is the sunscreen gap. It catches European brands off-guard because the two markets agree on almost everything in cosmetics regulation — except this. And the gap isn’t narrow.

Why Sunscreen Sits in Two Completely Different Regulatory Boxes

In the European Union, sunscreens are cosmetic products. Full stop. Regulation (EC) No 1223/2009 governs them, UV filters are listed in Annex VI of that regulation, and the route to market runs through a Product Information File (PIF) and CPNP notification. There’s no separate drug application, no clinical efficacy dossier to a pharmaceutical authority. If your UV filter appears in Annex VI and is used within its listed maximum concentration, you have a legal path to market.

In the United States, sunscreens are Over-The-Counter (OTC) drugs regulated by the FDA under 21 CFR. They’re treated in the same regulatory category as antacids and antihistamines. That classification has enormous practical consequences: your label requires a Drug Facts box in a prescribed format, your manufacturing facility must comply with pharmaceutical cGMP (21 CFR Part 211 — not the cosmetic-grade equivalent), and only active ingredients that FDA has found safe and effective may appear in your formula.

The FDA’s framework for sunscreen actives is the OTC Drug Monograph system. Under the final administrative order issued in September 2021 (OTC000013), FDA evaluated 16 UV filter ingredients. Two — zinc oxide and titanium dioxide — were classified as GRASE (generally recognized as safe and effective). Two — aminobenzoic acid (PABA) and trolamine salicylate — were prohibited. The remaining 12, including avobenzone, oxybenzone, octinoxate, and octocrylene, were placed in a “more data needed” category: they may remain on market while additional safety data is gathered, but their long-term regulatory status is unresolved.

Notice what’s absent from that list of 16. Every modern UV filter developed in Europe over the past 25 years.

The UV Filter Gap: Where European Formulations Hit the Wall

European formulators work with a considerably broader UV filter toolkit. Annex VI of Regulation (EC) No 1223/2009 currently lists more than 27 approved UV filter substances, with the SCCS (Scientific Committee on Consumer Safety) actively evaluating new candidates. The actives that sit beyond the US monograph’s reach include some of the most effective available:

Tinosorb S (Bemotrizinol) and Tinosorb M (Bisoctrizole) are both BASF actives offering excellent broad-spectrum UVA/UVB protection. Both are widely used in European premium SPF products. Neither is approved for use in the US. The FDA received Time and Extent Applications (TEAs) for both under the Sunscreen Innovation Act (SIA) enacted in 2014, but — after more than a decade — no final approval has followed. FDA’s requests for additional systemic absorption data have gone largely unanswered at scale.

Mexoryl SX (Ecamsule) and Mexoryl XL (Drometrizole Trisiloxane) are L’Oréal’s proprietary UVA filters, standard in French pharmacy sunscreens. Ecamsule is the single non-monograph UV filter to have received FDA approval — but only through a New Drug Application (NDA), and only for L’Oréal’s Anthelios SX product specifically. No other brand can freely use it. Mexoryl XL has no US approval at all.

DHHB (Diethylamino Hydroxybenzoyl Hexyl Benzoate, sold commercially as Uvinul A Plus by BASF) is another modern UVA filter standard in European premium formulations. It also has no US regulatory status.

The practical consequence is stark. A European brand formulating a genuinely high-performance broad-spectrum SPF product — one that has earned dermatologist endorsements and consistent shelf space in French pharmacies — may find that 40–60% of its UV filter system uses ingredients that have no US regulatory status at all.

Reformulating for the US isn’t always clean either. Removing Tinosorb S or DHHB and replacing with avobenzone introduces photostability challenges. Avobenzone degrades under UV exposure unless paired with photostabilisers like octocrylene or polysilicone-15 — and those additions add further formulation complexity, not to mention cost.

What It Actually Takes to Launch an SPF Product in the US

European brands that want to sell sunscreens in the US have four realistic options. The trade-offs are significant, and the right choice depends on the product’s volume potential, brand positioning, and timeline.

Option 1: Reformulate using only US-monograph-compliant actives. This is the fastest route to market. Limiting your formula to zinc oxide, titanium dioxide, or the viable Category III actives means your product fits the existing OTC monograph framework without a new drug approval. You’ll need to confirm concentration maximums — zinc oxide and titanium dioxide are permitted up to 25% each, avobenzone up to 3%, for example — and ensure your label carries a properly formatted Drug Facts box. Manufacturing must occur at an FDA-registered drug establishment operating under pharmaceutical cGMP.

Option 2: Pursue the Sunscreen Innovation Act pathway. The SIA of 2014 created a dedicated route for non-monograph UV actives, with defined FDA review timelines. Manufacturers submit a New Ingredient Application (NIA) with safety and efficacy data; FDA then has specific timescales to respond. In practice, this pathway has been extraordinarily slow. As of mid-2026 — 11 years after the SIA was signed — no sunscreen active has been approved through it. Tinosorb S and Tinosorb M applications remain pending, stalled largely on FDA’s requests for additional systemic absorption studies.

Option 3: File a product-specific NDA. This is what L’Oréal did for Anthelios SX with ecamsule. An NDA approval covers a specific finished product formulation, not the active ingredient broadly. The cost — typically several million USD for the clinical dossier, toxicology package, and regulatory process — makes this viable only for very high-volume products with strong US market conviction.

Option 4: Remove SPF claims for the US SKU. This is more common than it might seem. Some European brands market their US product with no SPF designation, positioning it as a moisturiser or antioxidant treatment. The UV filters may still be present as formula components (as long as they’re not active drug ingredients by US definitions), but no sunscreen claims are made. It sidesteps the drug regulatory pathway entirely, but it also removes a key selling point and limits the product’s appeal in a market that has become highly SPF-aware.

Labeling and Manufacturing: The Details That Catch Brands Out

Beyond the UV filter gap, there are several recurring compliance errors we see when European brands attempt US market entry for SPF products.

Broad spectrum doesn’t mean the same thing on both sides. In the EU, broad spectrum protection is assessed through methods like ISO 24443, which measures in vitro UVA protection across the spectrum. In the US, FDA’s broad spectrum designation requires a critical wavelength ≥ 370 nm, also measured in vitro but under a specific FDA protocol. The test methods aren’t equivalent. A product already validated for EU broad spectrum labeling needs to be re-evaluated using the FDA methodology before that claim can appear on the US label.

The Drug Facts box is not optional formatting. EU cosmetics use a standard INCI ingredient list in descending weight order. US OTC drug labels require a Drug Facts box with a prescribed layout — active ingredients with their declared purpose listed first, followed by Uses, Warnings, Directions, Inactive Ingredients, and Questions contact. Font size, type area, and information hierarchy are all regulated under 21 CFR Part 201.66. European graphic designers and packaging teams accustomed to cosmetic label formats get this wrong consistently.

Water resistance claims are tightly defined. Under the FDA’s 2011 sunscreen labeling rule, the only permitted water resistance statements are “Water Resistant (40 minutes)” or “Water Resistant (80 minutes),” derived from standardised testing protocols. Terms like “waterproof,” “sweatproof,” or “all-day protection” are prohibited. All three appear routinely on European SPF packaging and must be removed entirely.

Facility registration is separate from cosmetics GMP. Sunscreen manufacturing facilities must be registered with FDA as drug establishments, and each finished product requires an NDC (National Drug Code) number under the drug listing system. Many European contract manufacturers hold ISO 22716 certification — which is excellent for EU cosmetics GMP compliance — but they are not registered with FDA as drug manufacturers. Confirming your CMO’s regulatory status before signing a manufacturing agreement is non-negotiable.

The Cross-Market Formulation Problem

A European brand that wants a unified product line — the same formula in Paris and New York — will almost certainly need to accept one of two compromises. Either the European formulation is constrained by US ingredient restrictions, losing access to the modern UV filters that make high-performance SPF possible, or a separate US-market SKU is maintained with its own development and regulatory overhead.

Neither is inherently wrong. Many brands maintain distinct EU and US formulations, treating them as market-specific products under the same brand identity. The critical thing is making that decision deliberately, during the product development cycle — not after 50,000 units of packaging have been printed.

Regulatory strategy for sunscreens needs to start at ingredient selection, not after formulation is locked. The question “which UV filters are we using?” should be asked in the same breath as “which markets are we targeting?” If US export is part of the brand’s three-year plan, that shapes the formulation brief from day one.

Our team works specifically with European cosmetics brands navigating this intersection. If you’re developing an SPF product with US market potential, we can help you map the UV filter landscape and structure a compliance pathway before your formulation is committed.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Talk to our team about EU market entry and US SPF compliance. Contact us

Related from our network

• FDA-registered cosmetic and OTC drug product testing in the US — Qalitex Laboratories provides ISO 17025-accredited testing for sunscreen actives, SPF claims, and broad spectrum validation under FDA protocols.
• Health Canada-compliant SPF and natural health product testing — Androxa supports Canadian market entry for European cosmetic and NHP brands, including sunscreen safety and efficacy data packages.